XNW28012

DRUG2 trials

Sponsors

Evopoint Biosciences Inc.

Conditions

Advanced Solid TumorsCervical CancersMetastatic Pancreatic CancerOvarian CancerPancreatic Carcinoma

Phase 1

Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

RecruitingNCT06799637

Evopoint Biosciences Inc.Advanced Solid Tumors, Cervical Cancers, Ovarian Cancer +1

Start: 2023-12-01End: 2026-12-31Target: 350Updated: 2026-04-15

Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer

Not yet recruitingNCT07707674

Evopoint Biosciences Inc.Metastatic Pancreatic Cancer

Start: 2026-07-30End: 2028-04-30Target: 24Updated: 2026-07-22

Related Papers

Safety, efficacy, and pharmacokinetics of XNW28012, a tissue factor antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor (TOP1i) payload, in patients with advanced solid tumors: Results from a phase I/II study.

Journal of Clinical Oncology2026-05-27